Report From the Cardio-Oncology Symposium at the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Annual Congress

References

• Zamorano JL , GottfridssonC, AsteggianoRet al. The cancer patient and cardiology. Eur. J. Heart Fail., 22, 2290–2309 (2020).
   PubMed Web of Science ®Google Scholar
• Herrmann J , LenihanD, ArmenianSet al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur. Heart J., 43, 280–299 (2022).
   PubMed Web of Science ®Google Scholar
• Zamorano JL , LancellottiP, MuñozDRet al. ESC Scientific Document Group, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J., 37, 2768–2801 (2016).
   PubMed Web of Science ®Google Scholar
• Pudil R , MuellerC, ČelutkienėJet al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur. J. Heart Fail., 22, 1966–1983 (2020).
   PubMed Web of Science ®Google Scholar
• Cardinale D , IacopoF, CipollaCM. Cardiotoxicity of anthracyclines. Front. Cardiovasc. Med., 7, 26 (2020).
   PubMed Web of Science ®Google Scholar
• Cardinale D , CiceriF, LatiniRet al. ICOS-ONE study investigators. Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. Eur. J. Cancer, 94, 126–137 (2018).
   PubMed Web of Science ®Google Scholar
• D’Alessandro R , MasaroneD, BuonoAet al. Natriuretic peptides: molecular biology, pathophysiology and clinical implications for the cardiologist. Future Cardiol., 9, 519–534 (2013).
   PubMedGoogle Scholar
• Forte M , MadonnaM, SchiavonSet al. Cardiovascular pleiotropic effects of natriuretic peptides. Int. J. Mol. Sci., 20 (16), 3874 (2019).
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P , NegishiT, SomersetEet al. SUCCOUR investigators. Strain-guided management of potentially cardiotoxic cancer therapy. J. Am. Coll. Cardiol., 77, 392–401 (2021).
   PubMed Web of Science ®Google Scholar
• Minotti G , MennaP, CamilliM, SalvatorelliE, LeviR. Beyond hypertension: diastolic dysfunction associated with cancer treatment in the era of cardio-oncology. Adv. Pharmacol., 94, 365–409 (2022).
   PubMedGoogle Scholar
• Minotti G , ReggiardoG, CamilliM, SalvatorelliE, MennaP. From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach. JACC CardioOncol., 4, 139–140 (2022).
   PubMedGoogle Scholar
• Totzeck M , MichelL, LinY, HerrmannJ, RassafT. Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. Eur. Heart J., 43, 1928–1940 (2022).
   PubMed Web of Science ®Google Scholar
• Saunderson CED , PleinS, ManistyCH. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur. Heart J. Cardiovasc. Imaging, 22, 383–396 (2021).
   PubMed Web of Science ®Google Scholar
• Čelutkienė J , PudilR, López-FernándezTet al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur. J. Heart Fail., 22, 1504–1524 (2020).
   PubMed Web of Science ®Google Scholar
• Omland T , HeckSL, GulatiG. The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol., 4, 19–37 (2022).
   PubMedGoogle Scholar
• Camilli M , DelBuono MG, MennaP, MinottiG. In ®Entresto we trust. Cardiooncology, 6, 25 (2020).
   PubMedGoogle Scholar
• Camilli M , DelBuono MG, CreaF, MinottiG. Acute heart failure 29 years after treatment for childhood cancer. JACC CardioOncol., 2, 316–319 (2020).
   PubMedGoogle Scholar
• Camilli M , BiscegliaI, CanaleMLet al. Sacubitril/valsartan in oncologic patients with cardiotoxicity: another weapon in our pharmacological armory?. G. Ital. Cardiol., 23, 278–285 (2022).
   Google Scholar
• Camilli M , LombardiM, ChiabrandoJGet al. Sodium-glucose cotransporter inhibitors reduce mortality and morbidity in patients with heart failure: evidence from a meta-analysis of randomized trials. Am. J. Ther., 29, e199–e204 (2021).
   PubMed Web of Science ®Google Scholar
• Camilli M , LombardiM, ChiabrandoJGet al. Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother., 7, e74–e76 (2021).
   PubMed Web of Science ®Google Scholar
• Sabatino J , DeRosa S, TammèLet al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc. Diabetol., 19, 66 (2020).
   PubMed Web of Science ®Google Scholar
• Quagliariello V , DeLaurentiis M, ReaDet al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc. Diabetol., 20, 150 (2021).
   PubMed Web of Science ®Google Scholar